

0350 #10
Bot-seq

PATENT
Customer No. 22,852
Attorney Docket No. 07787.0042

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
James J. MOND et al.) Group Art Unit: 1653
)
Serial No.: 09/874,991) Examiner: Unassigned
)
Filed: June 7, 2001)
)
For: IMMUNOSTIMULATORY)
RNA/DNA HYBRID MOLECULES)

Commissioner for Patents and Trademarks
Washington, DC 20231

Sir:

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

This paper is being filed in response to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("the Notice") dated May 14, 2002.

In the Notice, the Office indicated that the Sequence Listing submission, filed on December 18, 2001, failed to comply with the requirements of 37 C.F.R. 1.822 and/or 1.823. Applicant's enclose and file herewith revised paper and computer readable copies of the Sequence Listing.

Applicants note that the <212> and/or <223> entries for SEQ ID NOS. 2-10 have been edited to correctly indicate that the oligonucleotide sequences presented are

FINNEGAN
HENDERSON
FARABOW
CARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

composed of entirely DNA, entirely RNA, or both DNA and RNA. As these changes merely reflect the composition of the oligonucleotides disclosed in the specification as filed no new matter is being added.

To the extent any extension of time under 37 C.F.R. § 1.136 is required to obtain entry of this response, such extension is hereby respectfully requested and authorization is hereby granted to charge any such extension fee to our Deposit Account No. 06-0916. If there are any fees due under 37 C.F.R. §§ 1.16 or 1.17 which are not enclosed herewith, please similarly charge such fees to our Deposit Account No. 06-0916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: July 15, 2002

By: *Tim Pollock* Reg. No. 43,592 for:
Robert A. Pollock
Reg. No. 43,008

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/874,991	06/07/2001	James J. Mond	07787.0042

22852
FINNEGAN, HENDERSON, FARABOW, GARRETT &
DUNNER LLP
1300 I STREET, NW
WASHINGTON, DC 20005

CONFIRMATION NO. 5537

FORMALITIES LETTER



OC00000008107987

Date Mailed: 05/14/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE